Dingell, Stupak Investigating Vytorin Clinical Trial

Drug Industry Daily
A A
Reps. John Dingell (D-Mich.) and Bart Stupak (D-Mich.) asked Merck and Schering-Plough to explain their delay in releasing data from a clinical trial of the cholesterol drug Vytorin.

To View This Article:

Login

Subscribe To Drug Industry Daily